Why Your Berberine Failed: RevGenetics Unveils the Absorption Gap Solution
PrAtlas/22796326

MIAMI - PrAtlas -- RevGenetics is disrupting the metabolic support market today with the commercial launch of DiBerberine 300x, an advanced enteric-coated dihydroberberine (DHB) supplement. By directly addressing the industry-wide "berberine absorption gap," RevGenetics exposes a flaw found in nearly every major competing brand: the failure to protect the active compound from stomach acid degradation and P-glycoprotein (P-gp) efflux pumps.

"The question we kept asking was: why is the supplement industry selling a mechanism - AMPK activation - with a delivery system that undermines the mechanism?" said RevGenetics founder Anthony Loera. "Most every major brand in the berberine category is selling a standard vegetarian capsule with berberine. Nobody in the supplement industry was solving them in a single product."

More on PrAtlas

• Tru by Hilton El Paso Airport Opens to Guests
• Zenylitics Announces Leadership Transition to Continue Accelerated Growth
• Wellness Technology Distributor Helping People Set Up Wellness Center Businesses
• Christian Apocalyptic Thriller Explores Biblical Prophecy, Global Technology, & the Rise of the Ant
• The Hidden Price Of Lost Property In UK Schools

Unlike standard formulas, The DiBerberine 300x Triple-Action Protocol sets a new standard by combining:

• Enteric Capsule Technology: Borrowing from pharmaceutical methods, this acid-resistant capsule bypasses the stomach without dissolving, preventing DHB from reverting to standard berberine HCl and ensuring release in the small intestine.
• DiBerberine™ Proprietary Blend (500mg per capsule): This leverages the profound pharmacokinetic advantage of DHB. A 2022 study showed a 100mg dose yielded ~6.7x greater plasma exposure than 500mg of standard berberine HCl.
• RGBooster1™: A patent-pending (U.S. App. No. 63/837,080) flavonoid complex. Internal assays demonstrate our Sophora japonica extract is up to 300x more potent than piperine at modulating the P-gp active transport mechanism that expels compounds from intestinal cells.

"Enteric coating isn't new technology," Loera stated. "Applying that technology to DHB was the obvious move. It just hadn't been done in a commercially available formula."

More on PrAtlas

• Milton Collier, CEO & President of Freight Broker 911, Eliminates the #1 Barrier to Entry in Logistics: Announces 100% Free Freight Broker Training
• FDA-Cleared AI Neuropsychiatry Platform, Million-Dose Ketamine Manufacturing and Presidential Psychedelic Initiative Drive Growing Momentum for NRXP
• AI Velocity Trading Launches Institutional-Grade Algorithmic Engine for Retail Investors
• Speaker and Certified Coach Syrena N. Williams Debuts Powerful New Book on Healing, Identity, and Wholeness
• Kryptokasinot.io Raises Concerns Over Proposed Cryptocurrency Restrictions in Finland's Gambling Reform

Manufactured in the USA in a cGMP-certified, third-party tested facility, DiBerberine 300x is now available at revgenetics.com. A 30-day supply (30 enteric capsules) is priced at $44.95.

Health and wellness influencers, practitioners, and marketers interested in partnering with RevGenetics for this launch can access the affiliate program at getlink.revgenetics.com.